Dapirolizumab pegol was better than a placebo at controlling disease activity in systemic lupus erythematosus patients in a Phase 3 trial.

Objective Systemic lupus erythematosus (SLE) is an autoimmune disease characterised by a loss of immune tolerance, affecting ...

Fate Therapeutics' FT522 explores treatments for lymphoma and autoimmune disorders. Read why FATE stock remains a top pick in ...

Predictors of developing PsA among patients with arthralgia at risk for progression included a family history of psoriasis and specific ultrasound features.

Columnist Marisa Zeppieri welcomes the season of holiday food while offering tips to get people with lupus through any ...

DelveInsight's 'Systemic Lupus Erythematosus Pipeline Insight 2024' report provides comprehensive global coverage of pipeline ...

The American College of Rheumatology (ACR) 2024 Convergence has just concluded, showcasing significant advancements and ...

In this study, we analysed 31 patients with SLE, mostly due to active steroid-resistant haematological involvement and/or ...

Discover how targeting E3-X ligase could revolutionize SLE treatment by enhancing anti-inflammatory effects while reducing ...

They also conditionally recommend performing a kidney biopsy in patients with SLE who have high levels of protein in the urine (> 0.5 g/g ... and changes in mental status and/or motor and sensory ...

Exagen Inc., a leading provider of autoimmune testing, today announced the validation and regulatory submission for approval of new Systemic Lupus Erythematosus (SLE) and rheumatoid arthritis (RA) ...